JP2002516873A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2002516873A5 JP2002516873A5 JP2000551796A JP2000551796A JP2002516873A5 JP 2002516873 A5 JP2002516873 A5 JP 2002516873A5 JP 2000551796 A JP2000551796 A JP 2000551796A JP 2000551796 A JP2000551796 A JP 2000551796A JP 2002516873 A5 JP2002516873 A5 JP 2002516873A5
- Authority
- JP
- Japan
- Prior art keywords
- cyclosporin
- meleu
- hydroxy
- group
- meile
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 description 24
- 230000001506 immunosuppresive Effects 0.000 description 13
- 108010036949 Cyclosporine Proteins 0.000 description 12
- 229960001265 ciclosporin Drugs 0.000 description 12
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 description 11
- 102000001493 Cyclophilins Human genes 0.000 description 11
- 108010068682 Cyclophilins Proteins 0.000 description 11
- 206010003246 Arthritis Diseases 0.000 description 10
- RPJPZDVUUKWPGT-FOIHOXPVSA-N NIM811 Chemical compound CC[C@H](C)[C@@H]1N(C)C(=O)CN(C)C(=O)[C@H](CC)NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC1=O RPJPZDVUUKWPGT-FOIHOXPVSA-N 0.000 description 10
- 125000000217 alkyl group Chemical group 0.000 description 10
- 241001465754 Metazoa Species 0.000 description 8
- 201000010099 disease Diseases 0.000 description 8
- 239000000203 mixture Substances 0.000 description 8
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 8
- 230000001363 autoimmune Effects 0.000 description 7
- 206010003816 Autoimmune disease Diseases 0.000 description 6
- 125000004432 carbon atoms Chemical group C* 0.000 description 6
- 230000002757 inflammatory Effects 0.000 description 6
- 229910052757 nitrogen Inorganic materials 0.000 description 6
- KSPIYJQBLVDRRI-WDSKDSINSA-N N-methyl-L-isoleucine Chemical compound CC[C@H](C)[C@H](NC)C(O)=O KSPIYJQBLVDRRI-WDSKDSINSA-N 0.000 description 5
- AKCRVYNORCOYQT-UHFFFAOYSA-N N-methylvaline Chemical compound CNC(C(C)C)C(O)=O AKCRVYNORCOYQT-UHFFFAOYSA-N 0.000 description 5
- 241000700159 Rattus Species 0.000 description 5
- 230000002265 prevention Effects 0.000 description 5
- 125000004453 alkoxycarbonyl group Chemical group 0.000 description 4
- 150000001413 amino acids Chemical class 0.000 description 4
- 125000004429 atoms Chemical group 0.000 description 4
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 description 4
- 238000004166 bioassay Methods 0.000 description 4
- 229910052736 halogen Inorganic materials 0.000 description 4
- 125000005842 heteroatoms Chemical group 0.000 description 4
- 125000000623 heterocyclic group Chemical group 0.000 description 4
- 125000004435 hydrogen atoms Chemical class [H]* 0.000 description 4
- 229910052760 oxygen Inorganic materials 0.000 description 4
- 229910052717 sulfur Chemical group 0.000 description 4
- 230000002522 swelling Effects 0.000 description 4
- AHQFCPOIMVMDEZ-UNISNWAASA-N (E,2S,3R,4R)-3-hydroxy-4-methyl-2-(methylamino)oct-6-enoic acid Chemical group CN[C@H](C(O)=O)[C@H](O)[C@H](C)C\C=C\C AHQFCPOIMVMDEZ-UNISNWAASA-N 0.000 description 3
- LXZHHFFYSBIHSF-AYNMCBCYSA-N Sanglifehrin A Chemical compound N1C(=O)C(CC)CC(C)C21C(C)=CC(C)C(CC(O)C(C)CC\C=C\C=C(/C)C1OC(=O)C3CCCN(N3)C(=O)C(CC=3C=C(O)C=CC=3)NC(=O)C(C(C)C)NC(=O)C(CCC(C)=O)C(O)C(C)C(O)/C=C/C=C/C1)O2 LXZHHFFYSBIHSF-AYNMCBCYSA-N 0.000 description 3
- 230000000694 effects Effects 0.000 description 3
- 229910052739 hydrogen Inorganic materials 0.000 description 3
- 239000001257 hydrogen Substances 0.000 description 3
- 230000004968 inflammatory condition Effects 0.000 description 3
- 230000002401 inhibitory effect Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000011780 sodium chloride Substances 0.000 description 3
- FYCWLJLGIAUCCL-DMTCNVIQSA-N (2S,3R)-2-azaniumyl-3-methoxybutanoate Chemical compound CO[C@H](C)[C@H](N)C(O)=O FYCWLJLGIAUCCL-DMTCNVIQSA-N 0.000 description 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 description 2
- 102000008186 Collagen Human genes 0.000 description 2
- 108010035532 Collagen Proteins 0.000 description 2
- 206010012601 Diabetes mellitus Diseases 0.000 description 2
- 108010002350 Interleukin-2 Proteins 0.000 description 2
- 206010072736 Rheumatic disease Diseases 0.000 description 2
- 125000003342 alkenyl group Chemical group 0.000 description 2
- 125000003545 alkoxy group Chemical group 0.000 description 2
- 125000003282 alkyl amino group Chemical group 0.000 description 2
- 125000002947 alkylene group Chemical group 0.000 description 2
- 125000000539 amino acid group Chemical group 0.000 description 2
- 201000009596 autoimmune hypersensitivity disease Diseases 0.000 description 2
- 229960005188 collagen Drugs 0.000 description 2
- 229920001436 collagen Polymers 0.000 description 2
- 125000002993 cycloalkylene group Chemical group 0.000 description 2
- 125000004663 dialkyl amino group Chemical group 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- -1 glyceraldehyde phosphate phosphorus Chemical compound 0.000 description 2
- 125000005843 halogen group Chemical group 0.000 description 2
- 150000002367 halogens Chemical class 0.000 description 2
- 125000001072 heteroaryl group Chemical group 0.000 description 2
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 2
- IJGRMHOSHXDMSA-UHFFFAOYSA-N nitrogen Substances N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 description 2
- 125000004433 nitrogen atoms Chemical group N* 0.000 description 2
- QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 description 2
- 125000003431 oxalo group Chemical group 0.000 description 2
- 239000001301 oxygen Chemical group 0.000 description 2
- MYMOFIZGZYHOMD-UHFFFAOYSA-N oxygen Chemical group O=O MYMOFIZGZYHOMD-UHFFFAOYSA-N 0.000 description 2
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 2
- 238000003571 reporter gene assay Methods 0.000 description 2
- NINIDFKCEFEMDL-UHFFFAOYSA-N sulfur Chemical group [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 2
- 239000011593 sulfur Chemical group 0.000 description 2
- 201000010874 syndrome Diseases 0.000 description 2
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 description 2
- QOHXNQDCNOQMFX-WMKHIVJLSA-N (3S,6S,9R,12S,18S,21S,24S,27R,30S,33S)-15-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-12-(1-methoxyethyl)-1,4,7,9,10,16,19,22,25,27,30-undecamethyl-6,21,24,33-tetrakis(2-methylpropyl)-3,18-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacon Chemical compound COC(C)[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)N(C)C1=O QOHXNQDCNOQMFX-WMKHIVJLSA-N 0.000 description 1
- VUWSWPYKHIQDQC-CZTSCGDPSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(1R,2R)-1-hydroxy-2-methylhexyl]-24-(2-hydroxy-2-methylpropyl)-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2, Chemical compound CCCC[C@@H](C)[C@@H](O)C1N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)(C)O)N(C)C(=O)CN(C)C(=O)[C@H](CC)NC1=O VUWSWPYKHIQDQC-CZTSCGDPSA-N 0.000 description 1
- BQQHPBPTWWXRMU-RQGXSBCFSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,22,25,28-decamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17, Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O BQQHPBPTWWXRMU-RQGXSBCFSA-N 0.000 description 1
- UUDGYAWEAWOYIK-JEKKPDPNSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18-tris(2-methylpropyl)-3,21,24-tri(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17,20,23, Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)N(C)C(=O)CN(C)C1=O UUDGYAWEAWOYIK-JEKKPDPNSA-N 0.000 description 1
- ZPZHKIOMBYYVRD-ZEEYZGKOSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S)-33-[(E,1R,2R)-1,6-dihydroxy-2-methylhex-4-enyl]-30-ethyl-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical compound CC[C@@H]1NC(=O)C([C@H](O)[C@H](C)C\C=C\CO)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O ZPZHKIOMBYYVRD-ZEEYZGKOSA-N 0.000 description 1
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 description 1
- 208000007502 Anemia Diseases 0.000 description 1
- 206010002967 Aplastic anaemia Diseases 0.000 description 1
- 208000006673 Asthma Diseases 0.000 description 1
- 206010004161 Basedow's disease Diseases 0.000 description 1
- 208000009137 Behcet Syndrome Diseases 0.000 description 1
- 201000008335 Behcet's disease Diseases 0.000 description 1
- 206010004661 Biliary cirrhosis primary Diseases 0.000 description 1
- 102000004631 Calcineurin Human genes 0.000 description 1
- 108010042955 Calcineurin Proteins 0.000 description 1
- 206010009900 Colitis ulcerative Diseases 0.000 description 1
- 102000000503 Collagen Type II Human genes 0.000 description 1
- 108010041390 Collagen Type II Proteins 0.000 description 1
- 206010011401 Crohn's disease Diseases 0.000 description 1
- 229940119017 Cyclosporine Drugs 0.000 description 1
- 108010036941 Cyclosporins Proteins 0.000 description 1
- 206010061818 Disease progression Diseases 0.000 description 1
- 206010013774 Dry eye Diseases 0.000 description 1
- 208000000999 Encephalomyelitis, Autoimmune, Experimental Diseases 0.000 description 1
- 206010015150 Erythema Diseases 0.000 description 1
- 206010018364 Glomerulonephritis Diseases 0.000 description 1
- 206010072579 Granulomatosis with polyangiitis Diseases 0.000 description 1
- 208000003807 Graves Disease Diseases 0.000 description 1
- 201000004779 Graves' disease Diseases 0.000 description 1
- 208000005209 Hematologic Disease Diseases 0.000 description 1
- 208000007475 Hemolytic Anemia Diseases 0.000 description 1
- 206010019755 Hepatitis chronic active Diseases 0.000 description 1
- 206010021245 Idiopathic thrombocytopenic purpura Diseases 0.000 description 1
- 206010062016 Immunosuppression Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 206010021972 Inflammatory bowel disease Diseases 0.000 description 1
- 208000006897 Interstitial Lung Disease Diseases 0.000 description 1
- 206010023232 Joint swelling Diseases 0.000 description 1
- 210000001503 Joints Anatomy 0.000 description 1
- 206010023332 Keratitis Diseases 0.000 description 1
- 208000009319 Keratoconjunctivitis Sicca Diseases 0.000 description 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 1
- 208000004883 Lipoid Nephrosis Diseases 0.000 description 1
- 206010028417 Myasthenia gravis Diseases 0.000 description 1
- 241000187480 Mycobacterium smegmatis Species 0.000 description 1
- 101700083238 NOTO Proteins 0.000 description 1
- 206010029164 Nephrotic syndrome Diseases 0.000 description 1
- 108009000551 Nephrotic syndrome Proteins 0.000 description 1
- 206010033645 Pancreatitis Diseases 0.000 description 1
- 206010037162 Psoriatic arthropathy Diseases 0.000 description 1
- 241000700157 Rattus norvegicus Species 0.000 description 1
- 206010038910 Retinitis Diseases 0.000 description 1
- 206010039073 Rheumatoid arthritis Diseases 0.000 description 1
- 206010043778 Thyroiditis Diseases 0.000 description 1
- 229940035295 Ting Drugs 0.000 description 1
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 description 1
- 206010046851 Uveitis Diseases 0.000 description 1
- 230000001154 acute Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000000240 adjuvant Effects 0.000 description 1
- 230000000947 anti-immunosuppressive Effects 0.000 description 1
- 230000003110 anti-inflammatory Effects 0.000 description 1
- 230000002917 arthritic Effects 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 230000001684 chronic Effects 0.000 description 1
- 239000002285 corn oil Substances 0.000 description 1
- 235000005687 corn oil Nutrition 0.000 description 1
- 230000002354 daily Effects 0.000 description 1
- 201000001981 dermatomyositis Diseases 0.000 description 1
- 201000002491 encephalomyelitis Diseases 0.000 description 1
- 230000002124 endocrine Effects 0.000 description 1
- 231100000321 erythema Toxicity 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 210000000548 hind-foot Anatomy 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- 125000001841 imino group Chemical group [H]N=* 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 238000002347 injection Methods 0.000 description 1
- 239000007924 injection Substances 0.000 description 1
- 201000010666 keratoconjunctivitis Diseases 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 238000005259 measurement Methods 0.000 description 1
- 239000002480 mineral oil Substances 0.000 description 1
- 235000010446 mineral oil Nutrition 0.000 description 1
- 201000006417 multiple sclerosis Diseases 0.000 description 1
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- OAICVXFJPJFONN-UHFFFAOYSA-N phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 description 1
- 229910052698 phosphorus Inorganic materials 0.000 description 1
- 239000011574 phosphorus Substances 0.000 description 1
- 230000002516 postimmunization Effects 0.000 description 1
- 201000002728 primary biliary cirrhosis Diseases 0.000 description 1
- 230000000750 progressive Effects 0.000 description 1
- 201000004681 psoriasis Diseases 0.000 description 1
- 201000001263 psoriatic arthritis Diseases 0.000 description 1
- 201000000306 sarcoidosis Diseases 0.000 description 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
- 230000001225 therapeutic Effects 0.000 description 1
- 201000006704 ulcerative colitis Diseases 0.000 description 1
- 125000002987 valine group Chemical group [H]N([H])C([H])(C(*)=O)C([H])(C([H])([H])[H])C([H])([H])[H] 0.000 description 1
- 239000003981 vehicle Substances 0.000 description 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB9811854.0 | 1998-06-02 | ||
| GBGB9811854.0A GB9811854D0 (en) | 1998-06-02 | 1998-06-02 | Organic compounds |
| PCT/EP1999/003770 WO1999062540A1 (en) | 1998-06-02 | 1999-05-31 | Use of cyclosporins in the treatment of inflammatory autoimmune diseases |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009252882A Division JP2010059177A (ja) | 1998-06-02 | 2009-11-04 | 炎症性自己免疫疾患の処置におけるサイクロスポリン類の使用 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2002516873A JP2002516873A (ja) | 2002-06-11 |
| JP2002516873A5 true JP2002516873A5 (no) | 2006-07-20 |
| JP4523154B2 JP4523154B2 (ja) | 2010-08-11 |
Family
ID=10833083
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2000551796A Expired - Fee Related JP4523154B2 (ja) | 1998-06-02 | 1999-05-31 | 炎症性自己免疫疾患の処置におけるサイクロスポリン類の使用 |
| JP2009252882A Pending JP2010059177A (ja) | 1998-06-02 | 2009-11-04 | 炎症性自己免疫疾患の処置におけるサイクロスポリン類の使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2009252882A Pending JP2010059177A (ja) | 1998-06-02 | 2009-11-04 | 炎症性自己免疫疾患の処置におけるサイクロスポリン類の使用 |
Country Status (17)
| Country | Link |
|---|---|
| EP (1) | EP1082130A1 (no) |
| JP (2) | JP4523154B2 (no) |
| KR (1) | KR20010043969A (no) |
| CN (1) | CN1304315A (no) |
| AU (1) | AU750422B2 (no) |
| BR (1) | BR9910860A (no) |
| CA (1) | CA2333315A1 (no) |
| GB (1) | GB9811854D0 (no) |
| HU (1) | HUP0102142A3 (no) |
| ID (1) | ID27576A (no) |
| IL (1) | IL139589A0 (no) |
| NO (1) | NO20006113L (no) |
| PL (1) | PL344451A1 (no) |
| SK (1) | SK18142000A3 (no) |
| TW (2) | TWI250021B (no) |
| WO (1) | WO1999062540A1 (no) |
| ZA (1) | ZA200006464B (no) |
Families Citing this family (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP1223971B1 (en) | 1999-10-27 | 2005-06-08 | Alexandra Lucas | Compositions for preventing and treating transplant rejection |
| WO2002026245A2 (en) * | 2000-09-29 | 2002-04-04 | Zhong Z Robert | Use of serp-1 in combination with an immunosuppressant for influencing inflammatory and immune reactions |
| GB0320638D0 (en) * | 2003-09-03 | 2003-10-01 | Novartis Ag | Organic compounds |
| AU2005230400A1 (en) * | 2004-04-08 | 2005-10-20 | Novartis Ag | Use of cyclosporins for treatment of cerebral ischemia and brain and spinal cord injury |
| ES2359925T3 (es) | 2004-07-14 | 2011-05-30 | Novartis Ag | Uso de una combinación de ciclosporina e interferones pegilados para tratar la hepatitis c (hcv). |
| DK1793844T3 (da) * | 2004-10-01 | 2011-03-21 | Debiopharm Sa | Anvendelse af [D-MeAla]3-[EtVal]4-cyklosporin til behandling af hepatitis C-infektion |
| US7285530B2 (en) | 2004-10-21 | 2007-10-23 | Viron Therapeutics, Inc. | Use of SERP-1 as an antiplatelet agent |
| CA2587586A1 (en) * | 2004-12-23 | 2006-07-06 | Novartis Ag | Compounds for flaviviridae treatment |
| RU2007128099A (ru) | 2004-12-23 | 2009-01-27 | Новартис АГ (CH) | Композиции для лечения гепатита с |
| AU2006259348B2 (en) * | 2005-06-17 | 2010-07-22 | Novartis Ag | Use of sanglifehrin in HCV |
| JP2007112775A (ja) * | 2005-10-24 | 2007-05-10 | Hamamatsu Univ School Of Medicine | サイトメガロウイルス感染の処置におけるシクロスポリン類の使用 |
| WO2010002428A2 (en) * | 2008-06-06 | 2010-01-07 | Scynexis, Inc. | Novel macrocyclic peptides |
| US20090306033A1 (en) * | 2008-06-06 | 2009-12-10 | Keqiang Li | Novel cyclic peptides |
| WO2010076329A1 (en) | 2008-12-31 | 2010-07-08 | Scynexis, Inc. | Derivatives of cyclosporin a |
| US20110144005A1 (en) * | 2009-12-09 | 2011-06-16 | Scynexis, Inc. | Novel cyclic peptides |
| CN104603146B (zh) | 2012-09-29 | 2018-01-02 | 诺华股份有限公司 | 环肽类化合物及其作为药物的用途 |
| CN104870007A (zh) * | 2012-10-19 | 2015-08-26 | 西尼克斯公司 | 新的抗病毒大环化合物 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SK278808B6 (sk) * | 1990-11-02 | 1998-03-04 | Novartis Ag | Cyklosporíny, ich použitie pri príprave liečiva na |
| AR006514A1 (es) * | 1995-07-04 | 1999-09-08 | Sandoz Ag | Un macrolido, sus usos, un proceso para producirlo, un aislado biologicamente puro capaz de producirlo, y una composicion farmaceutica quelo comprende |
| US6124453A (en) * | 1995-07-04 | 2000-09-26 | Novartis Ag | Macrolides |
| CZ288631B6 (cs) * | 1996-01-18 | 2001-08-15 | Galena, A. S. | Léčivé přípravky s obsahem cyklosporinu |
| CZ288739B6 (cs) * | 1996-08-01 | 2001-08-15 | Galena, A. S. | Cyklosporin obsahující léčivé přípravky |
-
1998
- 1998-06-02 GB GBGB9811854.0A patent/GB9811854D0/en not_active Ceased
-
1999
- 1999-05-31 PL PL99344451A patent/PL344451A1/xx not_active Application Discontinuation
- 1999-05-31 HU HU0102142A patent/HUP0102142A3/hu unknown
- 1999-05-31 KR KR1020007013585A patent/KR20010043969A/ko not_active Application Discontinuation
- 1999-05-31 CN CN99806904A patent/CN1304315A/zh active Pending
- 1999-05-31 JP JP2000551796A patent/JP4523154B2/ja not_active Expired - Fee Related
- 1999-05-31 EP EP99926489A patent/EP1082130A1/en not_active Withdrawn
- 1999-05-31 SK SK1814-2000A patent/SK18142000A3/sk unknown
- 1999-05-31 IL IL13958999A patent/IL139589A0/xx unknown
- 1999-05-31 ID IDW20002433A patent/ID27576A/id unknown
- 1999-05-31 BR BR9910860-7A patent/BR9910860A/pt not_active IP Right Cessation
- 1999-05-31 CA CA002333315A patent/CA2333315A1/en not_active Abandoned
- 1999-05-31 WO PCT/EP1999/003770 patent/WO1999062540A1/en not_active Application Discontinuation
- 1999-05-31 AU AU43724/99A patent/AU750422B2/en not_active Ceased
- 1999-06-01 TW TW094110378A patent/TWI250021B/zh not_active IP Right Cessation
- 1999-06-01 TW TW088109078A patent/TWI250022B/zh not_active IP Right Cessation
-
2000
- 2000-11-09 ZA ZA200006464A patent/ZA200006464B/en unknown
- 2000-12-01 NO NO20006113A patent/NO20006113L/no not_active Application Discontinuation
-
2009
- 2009-11-04 JP JP2009252882A patent/JP2010059177A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2002516873A5 (no) | ||
| JP2010059177A (ja) | 炎症性自己免疫疾患の処置におけるサイクロスポリン類の使用 | |
| US6809077B2 (en) | Cyclosporin analogs for the treatment of autoimmune diseases | |
| US6979671B2 (en) | Cyclosporins for the treatment of immune disorders | |
| US7012064B2 (en) | Cyclosporins for the treatment of immune disorders | |
| AU2008203031B2 (en) | Use of modified cyclosporins for the treatment of HCV disorders | |
| US9266927B2 (en) | Cyclosporin A analogs | |
| JP2008512351A5 (no) | ||
| RU2007105141A (ru) | Применение циклоспоринов для лечения болезни альцгеймера | |
| US20100130408A1 (en) | Use of modified cyclosporins | |
| CA2542507C (en) | Treatment of inflammatory bowel disease | |
| WO1993017039A1 (en) | Iso-cyclosporin salts | |
| GB2185886A (en) | Immunosuppressant agents containing ergot derivatives | |
| JPH0748246A (ja) | 徐放性注入剤 | |
| US20080194470A1 (en) | Nim811 In Cerebral Ischemia and Brain and Spinal Cord Injury | |
| ES2366538T3 (es) | Tratamiento de la enfermedad inflamatoria intestinal. | |
| AU2003269602B2 (en) | Treatment of inflammatory bowel disease | |
| RU2001101153A (ru) | Применение циклоспоринов для лечения воспалительных аутоиммунных заболеваний | |
| NZ576523A (en) | Use of modified cyclosporins | |
| AU2003269602A1 (en) | Treatment of inflammatory bowel disease |